The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity
Open accessAbstract
Mdm2, a key negative regulator of the p53 tumor suppressor, is a RING-type E3 ubiquitin ligase. The Mdm2 RING domain can be biochemically fractionated into two discrete species, one of which exists as higher order oligomers that are visible by electron microscopy, whereas the other is a monomer. Both fractions are ATP binding and E3 ligase activity competent, although the oligomeric fraction exhibits lower dependence on the E2 component of ubiquitin polymerization reactions. The extreme C-terminal five amino acids of Mdm2 are essential for E3 ligase activity in vivo and in vitro, as well as for oligomeric assembly of the protein. A single residue (phenylalanine 490) in that sequence is critical for both properties. Interestingly, the C-terminus of the Mdm2 homologue, MdmX (itself inert as an E3 ligase), can fully substitute for the equivalent segment of Mdm2 and restore its E3 activity. We further show that the Mdm2 C-terminus is involved in intramolecular interactions and can set up a platform for direct protein-protein interactions with the E2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Work from both the Vousden and Prives laboratories indicatesthat oligomeric Mdm2is a more effectivep53 ubiquitin ligase than is monomeric Mdm2 [27,28].”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [28]
In the citing paper
“Intriguingly, their data show that aromatic residues (Y489 and F490) outside the RING domain at the extreme C-terminus are also critical for Mdm2 ligase activity.”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [28]
In the citing paper
“Aromatic residues are conserved in the Mdmx C-terminal tail, and can also act in trans to reactivate E3 ligase function in Mdm2 C-terminal mutants [27,28].”
From The p53 orchestra: Mdm2 and Mdmx set the tone (2010) · cites this paper as [28]
In the citing paper
“Oligomerization of MDM2 RING domain increases its E3 ligase activity in vitro (Poyurovsky et al, 2007).”
From ATM activates p53 by regulating MDM2 oligomerization and E3 processivity (2009) · cites this paper as Poyurovsky et al, 2007
In the citing paper
“Formation of high-order oligomers is a common feature of RING domains (Kentsis et al, 2002;Poyurovsky et al, 2007).”
From ATM activates p53 by regulating MDM2 oligomerization and E3 processivity (2009) · cites this paper as Poyurovsky et al, 2007
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“…Harris and Levine, 2005; Poyurovsky and Prives, 2006), Mdm2 controls p53 through two distinct mechanisms, by directly binding and masking the N-terminal transactivation domain of p53 (Momand et al, 1992) and by promoting proteasomal degradation of p53 (Haupt et al, 1997; Kubbutat et al, 1997).”
BackgroundMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Enzyme structure and mechanism
Fersht, A. (1977) · Medical Entomology and Zoology · Cited by 2,875
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
Self-citationThe p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
Structure of the Cul1–Rbx1–Skp1–F boxSkp2 SCF ubiquitin ligase complex
Zheng, N., Schulman, B. A., Song, L., Miller, J. J., Jeffrey, P. D., Wang, P., Chu, C., Koepp, D. M., Elledge, S. J., Pagano, M., et al. (2002) · Nature · doi:10.1038/416703a · Cited by 1,507
Self-citationMdm2 Is a RING Finger-dependent Ubiquitin Protein Ligase for Itself and p53
Fang, S., Jensen, J. P., Ludwig, R. L., Vousden, K. H., & Weissman, A. M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.12.8945 · Cited by 1,044
Melnick, A. M., & Licht, J. D. (1999) · Blood · doi:10.1182/blood.v93.10.3167.410k44_3167_3215 · Cited by 1,029
Cited by
Sorted by citations
RING Domain E3 Ubiquitin Ligases
Deshaies, R. J., & Joazeiro, C. A. P. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.101807.093809 · Cited by 2,679
Kruse, J.-P., & Gu, W. (2009) · Cell · doi:10.1016/j.cell.2009.04.050 · Cited by 1,610
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
“The results of the analysis must be consid‐ ered preliminary as only a small number of patients (20) were enrolled.”
BackgroundRING-type E3 ligases: Master manipulators of E2 ubiquitin-conjugating enzymes and ubiquitination
Metzger, M. B., Pruneda, J. N., Klevit, R. E., & Weissman, A. M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.026 · Cited by 608
Signaling to p53: ribosomal proteins find their way
Zhang, Y., & Lu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.024 · Cited by 591
The p53 orchestra: Mdm2 and Mdmx set the tone
Wade, M., Wang, Y. V., & Wahl, G. M. (2010) · Trends in Cell Biology · doi:10.1016/j.tcb.2010.01.009 · Cited by 450
Lipkowitz, S., & Weissman, A. M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3120 · Cited by 422
Mdm2-mediated ubiquitylation: p53 and beyond
Marine, J.-C., & Lozano, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.68 · Cited by 354
The Roles of MDM2 and MDMX in Cancer
Karni-Schmidt, O., Lokshin, M., & Prives, C. L. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040349 · Cited by 302
Linke, K., Mace, P. D., Smith, C. A., Vaux, D. L., Silke, J., & Day, C. L. (2008) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402309 · Cited by 288
MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodelingPreprint
Venkatesh, D., O'Brien, N. A., Zandkarimi, F., Tong, D. R., Stokes, M. E., Dunn, D., Kengmana, E. S., Aron, A. T., Klein, A. M., Csuka, J. M., et al. (2020) · Genes & Development · doi:10.1101/gad.334219.119 · Cited by 274
Mechanism of p53 stabilization by ATM after DNA damage
Cheng, Q., & Chen, J. (2010) · Cell Cycle · doi:10.4161/cc.9.3.10556 · Cited by 264
Itahana, K., Mao, H., Jin, A., Itahana, Y., Clegg, H. V., Lindström, M. S., Bhat, K. P., Godfrey, V. L., Evan, G. I., & Zhang, Y. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.09.007 · Cited by 245
Shi, D., & Gu, W. J. (2012) · Genes & Cancer · doi:10.1177/1947601912455199 · Cited by 220
Ribosomal Protein S7 Is Both a Regulator and a Substrate of MDM2
Zhu, Y. Y., Poyurovsky, M. V., Li, Y., Biderman, L., Stahl, J., Jacq, X., & Prives, C. L. (2009) · Molecular Cell · doi:10.1016/j.molcel.2009.07.014 · Cited by 206
The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z.-G., Zuo, Y., Kawai, H., Shadfan, M., Ganapathy, S., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102309108 · Cited by 193
Ribosomal protein S14 unties the MDM2–p53 loop upon ribosomal stress
Zhou, X. Y., Hao, Q., Liao, J., Zhang, Q., & Lu, H. (2012) · Oncogene · doi:10.1038/onc.2012.63 · Cited by 176
Dai, M., Sun, X., & Lu, H. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01662-07 · Cited by 174
The regulation of MDM2 oncogene and its impact on human cancers
Zhao, Y., Yu, H., & Hu, W. (2014) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt147 · Cited by 181
An essential function of the extreme C-terminus of MDM2 can be provided by MDMX
Uldrijan, S., Pannekoek, W., & Vousden, K. H. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601469 · Cited by 170
A comprehensive framework of E2-RING E3 interactions of the human ubiquitin-proteasome system
van Wijk, S. J. L., de Vries, S. J., Kemmeren, P., Huang, A., Boelens, R., Bonvin, A. M. J. J., & Timmers, H. T. M. (2009) · Molecular Systems Biology · doi:10.1038/msb.2009.55 · Cited by 164
Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?
Wade, M., & Wahl, G. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0423 · Cited by 170
The role of ubiquitin modification in the regulation of p53
Hock, A. K., & Vousden, K. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.022 · Cited by 168
ATM activates p53 by regulating MDM2 oligomerization and E3 processivity
Cheng, Q., Chen, L., Li, Z., Lane, W. S., & Chen, J. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.294 · Cited by 165
Diaz‐Griffero, F., Qin, X.-R., Hayashi, F., Kigawa, T., Finzi, A., Sarnak, Z., Lienlaf, M., Yokoyama, S., & Sodroski, J. (2009) · Journal of Virology · doi:10.1128/jvi.01307-09 · Cited by 159
RING Domain–Mediated Interaction Is a Requirement for MDM2's E3 Ligase Activity
Kawai, H., Lopez-Pajares, V., Kim, M. M., Wiederschain, D., & Yuan, Z.-M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1313 · Cited by 160
Proteasome activator PA28γ regulates p53 by enhancing its MDM2‐mediated degradation
Zhang, Z., & Zhang, R. (2008) · The EMBO Journal · doi:10.1038/emboj.2008.25 · Cited by 151
The C terminus of p53 binds the N-terminal domain of MDM2
Poyurovsky, M. V., Katz, C., Laptenko, O., Beckerman, R., Lokshin, M., Ahn, J., Byeon, I. L., Gabizon, R., Mattia, M., Zupnick, A., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1872 · Cited by 153
Adaptor Protein Self-Assembly Drives the Control of a Cullin-RING Ubiquitin Ligase
Errington, W. J., Khan, M. Q., Bueler, S. A., Rubinstein, J. L., Chakrabartty, A., & Privé, G. G. (2012) · Structure · doi:10.1016/j.str.2012.04.009 · Cited by 140
Regulation of p53: a collaboration between Mdm2 and MdmX
Pei, D., Zhang, Y., & Zheng, J. (2012) · Oncotarget · doi:10.18632/oncotarget.443 · Cited by 140
Reactivation of p53: from peptides to small molecules
Brown, C. J., Cheok, C. F., Verma, C. S., & Lane, D. P. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.004 · Cited by 137
The roles and regulation of MDM2 and MDMX: it is not just about p53Preprint
Klein, A. M., de Queiroz, R. M., Venkatesh, D., & Prives, C. L. (2021) · Genes & Development · doi:10.1101/gad.347872.120 · Cited by 138
MDM2 and MDMX: Alone and together in regulation of p53.
Shadfan, M., Lopez-Pajares, V., & Yuan, Z.-M. (2012) · PubMed · Cited by 125
Quantitative analyses reveal the importance of regulated Hdmx degradation for p53 activation
Wang, Y. V., Wade, M., Wong, E., Li, Y.-C., Rodewald, L. W., & Wahl, G. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701497104 · Cited by 116
A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis
Wang, H., Ma, X., Ren, S., Buolamwini, J. K., & Yan, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0581 · Cited by 117
Tundo, G. R., Sbardella, D., Santoro, A. M., Coletta, A., Oddone, F., Grasso, G., Milardi, D., Lacal, P. M., Marini, S., Purrello, R., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107579 · Cited by 120
Saha, A., Murakami, M., Kumar, P., Bajaj, B. G., Sims, K., & Robertson, E. S. (2009) · Journal of Virology · doi:10.1128/jvi.02408-08 · Cited by 120
AMP-Activated Protein Kinase Induces p53 by Phosphorylating MDMX and Inhibiting Its Activity
He, G., Zhang, Y.-W., Lee, J., Zeng, S. X., Wang, Y. V., Luo, Z., Dong, X. C., Viollet, B., Wahl, G. M., & Lu, H. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00670-13 · Cited by 107
Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay
Herman, A. G., Hayano, M., Poyurovsky, M. V., Shimada, K., Skouta, R., Prives, C., & Stockwell, B. R. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0104 · Cited by 100
Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
Herrero, A. B., Rojas, E. A., Misiewicz-Krzemińska, I., Krzemiński, P., & Gutierrez, N. C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122003 · Cited by 102
Ubiquitin-mediated regulation of apoptosis
Broemer, M., & Meier, P. (2009) · Trends in Cell Biology · doi:10.1016/j.tcb.2009.01.004 · Cited by 97
Phosphatases in the cellular response to DNA damage
Freeman, A. K., & Monteiro, Á. N. A. (2010) · Cell Communication and Signaling · doi:10.1186/1478-811x-8-27 · Cited by 104
Zhang, J., Lei, Z., Huang, Z., Zhang, X., Zhou, Y., Luo, Z., Zeng, W., Su, J., Peng, C., & Chen, X. (2016) · Oncotarget · doi:10.18632/oncotarget.12836 · Cited by 91
Delineating Crosstalk Mechanisms of the Ubiquitin Proteasome System That Regulate Apoptosis
Gupta, I., Singh, K., Varshney, N. K., & Khan, S. M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00011 · Cited by 88
Mdm2 and Mdm4 Loss Regulates Distinct p53 Activities
Barboza, J., Iwakuma, T., Terzian, T., El‐Naggar, A. K., & Lozano, G. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2079 · Cited by 91
Small-molecule inhibitors of MDM2 as new anticancer therapeutics
Dickens, M. P., Fitzgerald, R. P., & Fischer, P. M. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.003 · Cited by 90
Mendoza, M. J., Mandani, G., & Momand, J. A. (2013) · BioMolecular Concepts · doi:10.1515/bmc-2013-0027 · Cited by 88
Lienlaf, M., Hayashi, F., Nunzio, F. D., Tochio, N., Kigawa, T., Yokoyama, S., & Diaz‐Griffero, F. (2011) · Journal of Virology · doi:10.1128/jvi.00497-11 · Cited by 91
Dysfunction of the MDM2/p53 axis is linked to premature aging
Lessel, D., Wu, D., Trujillo, C., Ramezani, T., Lessel, I., Alwasiyah, M. K., Saha, B., Hisama, F. M., Rading, K., Goebel, I., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92171 · Cited by 84
MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and BeyondPreprint
Marine, J., & Jochemsen, A. G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026237 · Cited by 82
Killing by Degradation: Regulation of Apoptosis by the Ubiquitin-Proteasome-System
Abbas, R., & Larisch, S. (2021) · Cells · doi:10.3390/cells10123465 · Cited by 91
Wang, Y. V., Leblanc, M., Wade, M., Jochemsen, A. G., & Wahl, G. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.05.008 · Cited by 79
Nie, J., Xie, P., Liu, L., Xing, G., Chang, Z., Yin, Y., Tian, C., He, F., & Zhang, L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.126920 · Cited by 79
Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase
Okamoto, K., Taya, Y., & Nakagama, H. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.07.021 · Cited by 76
Regulation of MDM2 E3 Ligase Activity by Phosphorylation after DNA Damage
Cheng, Q., Cross, B. L., Li, B., Chen, L., Li, Z., & Chen, J. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05553-11 · Cited by 78
Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity
Nomura, K., Klejnot, M., Kowalczyk, D., Hock, A. K., Sibbet, G. J., Vousden, K. H., & Huang, D. T. C. (2017) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3414 · Cited by 72
How to Inactivate Human Ubiquitin E3 Ligases by Mutation
Garcia-Barcena, C., Osinalde, N., Ramírez, J., & Mayor, U. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00039 · Cited by 79
Selective Cross-Linking of Interacting Proteins Using Self-Labeling Tags
Gautier, A., Nakata, E., Lukinavičius, G., Tan, K., & Johnsson, K. (2009) · Journal of the American Chemical Society · doi:10.1021/ja907818q · Cited by 72
Differential regulation of CFTRΔF508 degradation by ubiquitin ligases gp78 and Hrd1
Ballar, P., Örs, A. U., Yang, H., & Fang, S. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2009.10.005 · Cited by 71
Singh, R. K., Iyappan, S., & Scheffner, M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610879200 · Cited by 69
The long and the short of it: the MDM4 tail so far
Haupt, S., Mejía-Hernández, J. O., Vijayakumaran, R., Keam, S. P., & Haupt, Y. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz007 · Cited by 70
Auto-ubiquitination of Mdm2 Enhances Its Substrate Ubiquitin Ligase Activity
Ranaweera, R. S., & Yang, X. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.454470 · Cited by 73
E3 Ligases Determine Ubiquitination Site and Conjugate Type by Enforcing Specificity on E2 Enzymes
David, Y., Ternette, N., Edelmann, M. J., Ziv, T., Gayer, B., Sertchook, R., Dadon, Y., Kessler, B. M., & Navon, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.234559 · Cited by 72
Pierce, W. K., Grace, C. R., Lee, J., Nourse, A., Marzahn, M. R., Watson, E. R., High, A. A., Peng, J., Schulman, B. A., & Mittag, T. (2015) · Journal of Molecular Biology · doi:10.1016/j.jmb.2015.10.002 · Cited by 68
Tollini, L. A., Jin, A., Park, J., & Zhang, Y. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.006 · Cited by 66
Xiong, X., Zhao, Y., Tang, F., Wei, D., Thomas, D. G., Wang, X., Liu, Y., Zheng, P., & Sun, Y. (2014) · eLife · doi:10.7554/elife.02236 · Cited by 66
MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity
Stindt, M., Carter, S. A., Vigneron, A. M., Ryan, K. M., & Vousden, K. H. (2011) · Cell Cycle · doi:10.4161/cc.10.18.17436 · Cited by 62
Targeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 58
p53 ubiquitination by Mdm2: A never ending tail?
Coutts, A. S., Adams, C., & Thangue, N. B. L. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.01.008 · Cited by 56
Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice
Jung, C., Lim, J. H., Choi, Y., Kim, D., Kang, K. J., Noh, S., & Im, D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42674 · Cited by 56
Deubiquitinating enzyme regulation of the p53 pathway: A lesson from Otub1
Sun, X. (2014) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v5.i2.75 · Cited by 56
APC/CCdc20targets E2F1 for degradation in prometaphase
Peart, M. J., Poyurovsky, M. V., Kass, E. M., Urist, M. J., Verschuren, E. W., Summers, M. K., Jackson, P. K., & Prives, C. L. (2010) · Cell Cycle · doi:10.4161/cc.9.19.13162 · Cited by 52
Targeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapy
Allende-Vega, N., & Saville, M. K. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.004 · Cited by 51
Leslie, P. L., Ke, H., & Zhang, Y. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.644435 · Cited by 50
Targeting MDMX for Cancer Therapy: Rationale, Strategies, and Challenges
Yu, D.-H., Xu, Z., Mo, S., Li, Y., Cheng, X., & Qin, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01389 · Cited by 53
Wang, H., & Yan, C. (2011) · Neoplasia · doi:10.1593/neo.11438 · Cited by 50
Targeting the MDM2/MDM4 Interaction Interface as a Promising Approach for p53 Reactivation Therapy
Pellegrino, M., Mancini, F., Lucà, R., Coletti, A., Giacchè, N., Manni, I., Arisi, I., Florenzano, F., Teveroni, E., Buttarelli, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0439 · Cited by 49
Structural insight into UV-B–activated UVR8 bound to COP1
Wang, Y., Wang, L., Guan, Z., Chang, H., Ma, L., Shen, C., Qiu, L., Yan, J., Zhang, D., Li, J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn3337 · Cited by 47
Crosstalk Between the SUMO and Ubiquitin Pathways
Hunter, T. R., & Sun, H. (2008) · Ernst Schering Research Foundation workshop/Ernst Schering Foundation Symposium proceedings · doi:10.1007/2789_2008_098 · Cited by 47
Targeting TRIM Proteins: A Quest towards Drugging an Emerging Protein Class
D’Amico, F., Mukhopadhyay, R., Ovaa, H., & Mulder, M. P. C. (2021) · ChemBioChem · doi:10.1002/cbic.202000787 · Cited by 44
Small molecules that bind the Mdm2 RING stabilize and activate p53
Roxburgh, P., Hock, A. K., Dickens, M. P., Mezna, M., Fischer, P. M., & Vousden, K. H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs092 · Cited by 43
Marcar, L., Ihrig, B., Hourihan, J. M., Bray, S. E., Quinlan, P., Jordan, L. B., Thompson, A. M., Hupp, T. R., & Meek, D. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127713 · Cited by 42
Suppression of p53 activity by Siva1
Du, W., Jiang, P., Li, N., Mei, Y., Wang, X., Wen, L., Yang, X., & Wu, M. (2009) · Cell Death and Differentiation · doi:10.1038/cdd.2009.89 · Cited by 44
Structural and Functional Comparison of the RING Domains of Two p53 E3 Ligases, Mdm2 and Pirh2
Shloush, J., Vlassov, J. E., Engson, I., Duan, S., Saridakis, V., Dhe-paganon, S., Raught, B., Sheng, Y., & Arrowsmith, C. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.157669 · Cited by 42
MDM2 Promotes Proteasomal Degradation of p21Waf1 via a Conformation Change
Xu, H., Zhang, Z., Li, M., & Zhang, R. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.059568 · Cited by 41
MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation In Vivo
Yang, J., Jin, A., Han, J., Chen, X., Zheng, J., & Zhang, Y. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0790 · Cited by 39
MDM4 (MDMX) and its Transcript Variants
Mancini, F., Conza, G. D., & Moretti, F. (2009) · Current Genomics · doi:10.2174/138920209787581280 · Cited by 40
Otub1 stabilizes MDMX and promotes its proapoptotic function at the mitochondria
Chen, Y., Wang, Y.-G., Li, Y., Sun, X., & Dai, M. (2016) · Oncotarget · doi:10.18632/oncotarget.14278 · Cited by 38
Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain
Magnussen, H., Ahmed, S. F., Sibbet, G. J., Hristova, V. A., Nomura, K., Hock, A. K., Archibald, L. J., Jamieson, A. G., Fushman, D., Vousden, K. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15783-y · Cited by 37
Vitamin B6 regulates IL-33 homeostasis to alleviate type 2 inflammation
Zhu, S., Zhong, S., Cheng, K., Zhang, L., Bai, J., Cao, Z., Wang, S., Chen, W., Cheng, S., Ma, L., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01029-6 · Cited by 38
Gao, Y., Wang, Y., Xin, H., Li, S., & Liang, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-13513-x · Cited by 38
Functions of MDMX in the Modulation of the p53‐Response
Lenos, K., & Jochemsen, A. G. (2011) · BioMed Research International · doi:10.1155/2011/876173 · Cited by 40
Pettersson, S., Kelleher, M., Pion, E., Wallace, M., & Ball, K. L. (2008) · Biochemical Journal · doi:10.1042/bj20082087 · Cited by 37
Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif
Worrall, E. G., Wawrzynów, B., Worrall, L. J., Walkinshaw, M. D., Ball, K. L., & Hupp, T. R. (2009) · Journal of Chemical Biology · doi:10.1007/s12154-009-0019-5 · Cited by 35
Functions of p53 in metabolism and invasion
Vousden, K. H. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370511 · Cited by 36
CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells
Štětková, M., Growková, K., Fojtík, P., Valčíková, B., Palušová, V., Verlande, A., Jorda, R., Kryštof, V., Hejret, V., Alexiou, P., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02971-3 · Cited by 34
The roles of MDM2 and MDMX phosphorylation in stress signaling to p53
Chen, J. (2012) · Genes & Cancer · doi:10.1177/1947601912454733 · Cited by 33
Cytoplasmic tethering is involved in synergistic inhibition of p53 by Mdmx and Mdm2
Ohtsubo, C., Shiokawa, D., Kodama, M., Gaiddon, C., Nakagama, H., Jochemsen, A. G., Taya, Y., & Okamoto, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01180.x · Cited by 32
MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity
Chinnam, M., Xu, C., Lama, R., Zhang, X., Cedeno, C. D., Wang, Y., Stablewski, A. B., Goodrich, D. W., & Wang, X. (2022) · PLoS Genetics · doi:10.1371/journal.pgen.1010171 · Cited by 35
Doleželová, P., Cetkovská, K., Vousden, K. H., & Uldrijan, S. (2012) · Cell Cycle · doi:10.4161/cc.11.5.19445 · Cited by 33
Metadata
- Authors
- Poyurovsky, M. V., Priest, C., Kentsis, A., Borden, K. L., Pan, Z., Pavletich, N., & Prives, C.
- Affiliations
- Columbia University (US)
- New York University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Prives, Carol
- ORCID
- Venue
- The EMBO Journal
- Published
- 2006-12-14
- Volume
- 26
- Issue
- 1
- Pages
- 90-101
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- PMC
- PMC1782380
- OpenAlex
- W2123242499
- Cited by
- 203
- References
- 46
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 4 · 2023: 12 · 2022: 3 · 2021: 11 · 2020: 14 · 2019: 6 · 2018: 6 · 2017: 9 · 2016: 10 · 2015: 7 · 2014: 9 · 2013: 10 · 2012: 18
- FWCI
- 7.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The EMBO Journal (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (CA58316, CA87497)
- National Cancer Institute (R37CA058316, CA-87497, P01CA087497, R01CA058316, CA 58316)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- MDM2, RING domain, E3 ubiquitin ligase, protein oligomerization, supramolecular self-assembly, C-terminal domain, p53 regulation, MDMX, E2 ubiquitin-conjugating enzyme, intramolecular interactions, protein-protein interaction, ubiquitination
- MeSH terms
- Adenosine Triphosphate, Escherichia coli, Humans, Microscopy, Electron, Models, Biological, Nuclear Proteins, Phenylalanine, Protein Binding, Protein Conformation, Tumor Suppressor Protein p53, Protein Structure, Tertiary, Ubiquitin, Ubiquitin-Protein Ligases, Cell Line, Tumor, Proto-Oncogene Proteins c-mdm2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
